Stocks closed solidly higher on Thursday for the fourth straight session as investor optimism about the Trump administration continues to run high.
Elevance Health Inc. closed $174.10 below its 52-week high ($567.26), which the company achieved on September 3rd.
Shares of Elevance Health jumped early Thursday in response to better-than-expected fourth- quarter results, and a generally optimistic outlook for the coming year. A week after UnitedHealth Group cast a pall over the health insurance sector with a glum report on its own earnings,
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Elevance Health (ELV – Research Report), with a price target of $501.00. The company’s shares closed ...